Severity
Critical
FDA Drug recall · Reported February 5, 2014
Marketed Without An Approved NDA/ANDA: FDA analysis found MaXtremeZEN which is marketed as a dietary supplement to contain undeclared desmethyl carbondenafil and dapoxetine. Desm…
Ss Wholesale Inc. dba Jobbers Wholesale recalled MaXtremeZEN capsules, 1 capsule per blister pack, Distributed by: P&A Enterprise, Buena P… - a critical-severity action.
MaXtremeZEN capsules, 1 capsule per blister pack, Distributed by: P&A Enterprise, Buena P… was recalled by Ss Wholesale Inc. dba Jobbers Wholesale in February 5, 2014. Reason: Marketed Without An Approved NDA/ANDA: FDA analysis found MaXtremeZEN which is marketed as a dietary suppleme…. Check the official notice for the remedy. Verify recall #D-1046-2014 with the FDA Drug before acting.
The recall
Ss Wholesale Inc. dba Jobbers Wholesale issued this critical-severity FDA Drug recall-Marketed Without An Approved NDA/ANDA: FDA analysis found MaXtremeZEN which is marketed as a dietary suppleme….
Sourced from official FDA Drug enforcement records. Verify recall #D-1046-2014 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1046-2014) was formally reported on February 5, 2014, with the manufacturer initiating the action on November 18, 2013. It is classified under Critical severity (Class I), with a current status of Terminated. Ss Wholesale Inc. dba Jobbers Wholesale is listed as the recalling firm, operating out of Paramount, CA. Federal records list the affected scope as 2,395 blister packs total for all products.
The documented reason for this recall is: Marketed Without An Approved NDA/ANDA: FDA analysis found MaXtremeZEN which is marketed as a dietary supplement to contain undeclared desmethyl carbondenafil and dapoxetine. Desmethyl carbondenafil is a phosphodiestera… Distribution data in the federal record shows the product reached: CA. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified high severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Critical
Affected scope
2,395 blister packs total for all products
Related Recalls
6
5 from same agency
MaXtremeZEN capsules, 1 capsule per blister pack, Distributed by: P&A Enterprise, Buena Park, CA 90621, UPC 6 10079 52468 2.
Marketed Without An Approved NDA/ANDA: FDA analysis found MaXtremeZEN which is marketed as a dietary supplement to contain undeclared desmethyl carbondenafil and dapoxetine. Desmethyl carbondenafil is a phosphodiesterase (PDE)-5 inhibitors which is a class of drugs used to treat male erectile dysfunction, making this product an unapproved new drug. Dapoxetine is an active ingredient not approved
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Critical (Class I) |
| Status | Terminated |
| Recall number | D-1046-2014 |
| Date reported | February 5, 2014 |
| Date initiated | November 18, 2013 |
| Recalling firm | Ss Wholesale Inc. dba Jobbers Wholesale |
| Firm location | Paramount, CA |
| Affected scope | 2,395 blister packs total for all products |
| Distribution | CA |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported February 5, 2014. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.